Business & Industry
- Insilico Medicine receives IND approval for novel AI-designed USP1 inhibitor for cancer
- U.S. FDA approves ABRYSVO™, Pfizer's vaccine for the prevention of respiratory syncytial virus (RSV) in older adults
- Bayer launches unit to develop new precision health consumer products
- Pfizer's PAXLOVID™ receives FDA approval for adult patients at high risk of progression to severe COVID-19
- Insilico Medicine delivers preclinical candidate targeting ENPP1 for cancer immunotherapy and the treatment of rare disease using generative AI
Research & Development
- Researchers use ‘natural’ system to identify proteins most useful for developing an effective HIV vaccine
- New blood biomarker can predict if cognitively healthy elderly will develop Alzheimer's disease
- Large study provides scientists with deeper insight into long COVID symptoms
- Multivitamin improves memory in older adults, study finds
- Capturing transporter structure paves the way for drug development
- Delivering on the promise of personalized breast cancer therapy
- Researchers identify 10 pesticides toxic to neurons involved in Parkinson's
Conferences & Events
- Reduced cancer mortality with daily vitamin D intake
- Driving the potential of gene-based medicine through cutting-edge technologies to target undruggable diseases
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
Regulatory Affairs
- FDA approves first drug to treat agitation symptoms associated with dementia due to Alzheimer's disease
- FDA approves first respiratory syncytial virus (RSV) vaccine
- FDA approves cell therapy for patients with blood cancers to reduce risk of infection following stem cell transplantation
- FDA approves first over-the-counter naloxone nasal spray
- FDA grants Accelerated Approval for Alzheimer's disease treatment